CONTACT US

ABOUT IAMPS.

Why IAMPS?

Microphysiological Systems (MPS) are at a critical turning point. In 2025, international regulatory authorities—including the FDA, PMDA and MHRA—issued explicit guidance recognizing New Approach Methodologies (NAMs) as credible alternatives to animal models for specific contexts of use. This global momentum confirms the scientific maturity and regulatory relevance of MPS technologies.

While Europe pioneered this field and has long supported NAMs through its regulatory framework, its industrial MPS ecosystem remains fragmented and insufficiently structured to fully benefit from this global momentum. IAMPS was created to unite European MPS providers under a single industry voice, align complementary technologies, and provide clear industrial guidance to end-users navigating an increasingly complex landscape. Acting as a one-stop interface with regulatory bodies, IAMPS accelerates regulatory acceptance through coordinated engagement on validation, standardisation and methodology evaluation. Beyond market and regulation, IAMPS advocates at the European level to secure strategic autonomy, balanced industry representation and long-term infrastructures essential to establishing MPS as a strategic European technology.

MEMBERS

Executive Team.

Thibault HONEGGER, NETRI, President IAMPS.

Paola OCCHETTA, BiomimX, Vice-President for Regulatory Adoption and Partnerships IAMPS.

Jos JOORE, MIMETAS, Vice-President for Legislation and Programs IAMPS.

"We are at a critical moment for NAMs, with a strong push from international regulatory bodies in 2025, including explicit guidance for several contexts of use to phase out animal models. Although the EMA has been working on NAMs for a long time, there is an urgent need for the global health industry to work with industrial MPS providers. This will benefit both the needs of the global health industry as well as the expectations of regulatory agencies. Europe invented this field: now, we are organising amongst ourselves to own its future. As a joined IAMPS force, we're committed to establishing MPS as a strategic European technology, driving growth in the industry, as well as scientific progress and public health improvements. Together with Paola and Jos, and the support of our board of directors, IAMPS is ready to shape the future of NAMs in Europe, and throughout the world."
Thibault HONEGGERPresident
Thibault HONEGGER
“I strongly believe that IAMPS comes at a particularly timely and crucial moment to accelerate the adoption of New Approach Methodologies. By enabling us to speak with a strong, unified voice, IAMPS will support standardisation, validation, and constructive dialogue with regulators, accelerating the acceptance of MPS and strengthening Europe’s position as a global leader in advanced, human-relevant models.”
Paola OCCHETTA Vice-President for Regulatory Adoption and Partnerships
Paola OCCHETTA
"Microphysiological systems are revolutionizing drug development by being deeply human-relevant, scalable, and significantly transforming the discovery and evaluation of therapies. As the Vice-President for Legislation and Programmes at IAMPS, I am dedicated to shaping the global trajectory of MPS. Collaborating with leading innovators in the field, we aim to establish harmonized standards, secure regulatory confidence, and ensure the scientific rigor necessary to make MPS the worldwide norm for safe, rapid, and effective drug development."
Jos JOOREVice-President for Legislation and Programs
Jos JOORE

Board of Directors.

Nina Hobi

AlveoliX

Paola Occhetta

BiomimX

Dustin Dopsa

chiron

Martin Raasch

Dynamic42

Paul Clémençon

InSphero

Jos Joore

MIMETAS

Thibault Honegger

NETRI

Maurizio Aiello

React4Life

Reyk Horland

TissUse

Mission.

IAMPS brings together and represents companies developing Microphysiological Systems (MPS) across Europe, including organoids, organs-on-chips and related human biology–based technologies. As the world’s first industry association dedicated to MPS providers, IAMPS serves as a unified European industry voice to support the development, adoption and regulatory acceptance of these innovative New Approach Methodologies (NAMs).

IAMPS works constructively with European and international institutions, regulatory agencies, end-users and stakeholders to accelerate the industrial deployment of MPS, increase acceptance of MPS-derived data, advance qualification and standardisation, and contribute to the derisking of clinical development. Through collaboration, data sharing and coordinated industry action, IAMPS aims to strengthen Europe’s competitiveness in life sciences while supporting major public policy objectives, including improved public health and the reduction of animal testing.

Vision.

IAMPS envisions Europe as a global leader in Microphysiological Systems and New Approach Methodologies, with a strong, competitive and coordinated industrial ecosystem capable of shaping regulatory, scientific and technological future.

Building on Europe’s pioneering role in MPS innovation, IAMPS seeks to establish MPS as a strategic European technology by fostering regulatory trust, industrial scalability and long-term access to critical biological resources. By ensuring a balanced representation of industry alongside academia and by advocating for supportive funding and legislative frameworks, IAMPS aims to secure Europe’s autonomy, global influence and leadership in next-generation human-relevant research and development.